期刊
VACCINE
卷 30, 期 5, 页码 825-829出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2011.11.115
关键词
Adjuvant; Allergen-specific immunotherapy; Bifidobacteria; Probiotics; Regulatory T cells
资金
- European Union
- Spanish Plan Nacional de I+D [AGL2007-61805, AGL2010-14952]
- Spanish Ministerio de Ciencia e Innovacion (MICINN)
Allergen-specific immunotherapy is the only treatment shown to induce antigen-specific regulatory T (Treg) cells and peripheral tolerance to restore human homeostasis. Specific probiotic strains are valid candidates to improve the allergen-specific tolerance, since they are able to generate Treg cells from nave precursors. We recently reported that exposing dendritic cells (DCs) to Bifidobacterium bifidum LMG13195 in vitro induced the polarization of naive T cells into functional Treg cells. In the present study, we evaluated the ability of DCs exposed to different B. bifidum subcellular fractions to promote Treg differentiation. We found that DCs exposed to B. bifidum LMG13195 membrane vesicles most strongly promoted differentiation of functional CD25(high)FOXP3(high)CD127-(/low) Treg cells as well as induced the highest IL-10 levels respect to the proinflammatory cytokines IFN gamma, INF alpha and IL-17. Our results suggest the potential use of B. bifidum LMG13195 membrane vesicles as a safe and clinically effective adjuvant for immunotherapy. (C) 2011 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据